TGFB1 and colorectal carcinoma: A83-01 is a selective inhibitor of TGF-β receptor; it was shown to inhibit EMT in HER2-overexpressing breast cancer cells by interfering the TGF-β-induced upregulation of Wnt3 (91), whereas its application in treating CRC has not been reported.